% 0期刊文章%一个肖恩Pittock Dubey Divyanshu % %一个塞西莉亚凯利%安德鲁·麦肯% A塞巴斯蒂安Lopez-Chiriboga %一个Avi Gadoth万带兰列侬% %史密斯Carin %桑德拉科比%艾伦Aksamit克里斯托弗•克莱恩% %一个米歇尔•托莱达诺%布拉德利Boeve % 1月Mendelt Tillema % Eoin弗拉纳根% T的发病率和患病率自身免疫性脑炎和传染性脑炎的比较:以人群为基础的研究(P5.401) % D J神经病学2018% % P P5.401 % V 90% N 15补充% X目的:我们评估自身免疫性脑炎和发病率和患病率比较自身免疫性和传染性脑炎的流行病学。首页背景:以人群为基础的研究缺乏自身免疫性脑炎发病率和患病率。意识的流行病学是至关重要的资源配置和医疗保健计划。设计/方法:我们进行以人群为基础的发病率和患病率的比较研究自身免疫性和传染性脑炎在奥姆斯特德县,美国。自身免疫性脑炎诊断及其子组被定义为最近出版的诊断标准。年龄计算sex-adjusted患病率和发病率,并使用泊松回归相比。结果:自身免疫性脑炎的流行于2014年1月1日,13.2/100000没有明显不同于所有传染性脑炎(11.6/100000;p = 0.75)或病毒子类别(8.3/100000;p = 0.23)。自身免疫性的发病率(1995 - 2015)和传染性脑炎分别为0.8/100000和1.0/100000组(p = 0.58)。复发或复发住院比传染性高自身免疫性脑炎(p = 0.04)。 The incidence of autoimmune encephalitis increased over time from 0.4/100,000 person-years (1995–2005) to 1.2/100,000 person-years (2006–2015) (p=0.02), attributable to increased recognition of autoantibody-positive cases. The incidence (2.3 vs 0.7/100,000 person-years; p=0.01) and prevalence (38.3 vs 12.9/100,000; p=0.03) of autoimmune encephalitis was higher among African-Americans than Caucasians. Additionally, males had a significantly higher prevalence of autoimmune encephalitis than females (19.0 vs 7.2/100,000, p=0.04). The prevalence of specific neural autoantibody biomarkers among the definite autoimmune encephalitis category was: glutamic acid decarboxylase-65 (GAD65) (1.9/100,000); unclassified neural autoantibody (1.4/100,000); myelin-oligodendrocyte-glycoprotein (MOG) (1.3/100,000); leucine-rich glioma-inactivated-protein-1 (LGI1) (0.7/100,000); collapsin response-mediator protein-5 (CRMP5) (0.7/100,000); N-methyl-D-aspartate-receptor (NMDAR) (0.6/100,000); anti-neuronal nuclear antibody-2 (ANNA-2/anti-Ri) (0.6/100,000) and glial fibrillary acidic protein-α (GFAPα) (0.6/100,000).Conclusions: This study shows that the prevalence and incidence of autoimmune encephalitis is comparable to infectious encephalitis and its recognition is increasing over time.Disclosure: Dr. Dubey has nothing to disclose. Dr. Pittock has nothing to disclose. Dr. Kelly has nothing to disclose. Dr. McKeon has received research support from Medimmune, Euroimmun, Grifols and Alexion. Dr. Lopez has nothing to disclose. Dr. Lennon has received royalty, license fees, or contractual rights payments from RSR, royalties from sale kits for AQP4 IgG detetction and from clinical service assays performed outside Mayo clinic. Dr. Gadoth has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Bryant has nothing to disclose. Dr. Klein has nothing to disclose. Dr Aksamit has nothing to disclose. Dr. Toledano has nothing to disclose. Dr. Boeve has received research support from GE Heathcare and Axovant. Dr. Tillema has nothing to disclose. Dr Flanagan has nothing to disclose. %U